SAN DIEGO, Sept. 23, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and analyst event on Friday, October 4, 2019 from 8:00 a.m. to 11:30 a.m. ET in New York City, entitled "A New Chapter in PI3Kδ

MENLO PARK, Calif., Sept. 23, 2019 /PRNewswire/ -- Adicet Bio, Inc., a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced today the appointment of Francesco Galimi, M.D., Ph.D., as Senior Vice President and Chief Medical Officer. 

SALT LAKE CITY, Sept. 23, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that four abstracts (two oral presentations and two posters) will be presented at the

SAN DIEGO, Sept. 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Cantor Global Healthcare Conference in New York, NY.  Dr. Helen Torley, president and chief executive off

HOLYOKE, Mass., Sept. 23, 2019 /PRNewswire/ -- A coalition of nurses, mental health professionals, patients, families, elected officials and other community members who are fighting to preserve local inpatient behavioral health services will hold a rally on Monday, Sept. 23 in Holyoke to protest

ST. LOUIS, Sept. 23, 2019 /PRNewswire/ -- To the benefit of millions of people living with uncontrolled psoriasis worldwide, a global consortium of more than 100 physician leaders in dermatology led by the

LOS ANGELES, Sept. 23, 2019 /PRNewswire/ -- EPM, the first global company able to mass produce and supply synthetic and fully stable acid-based cannabinoid molecules, today announced it is launching a commercial platform that opens its intellectual property portfolio to the healthcare industry for potential licensing partnerships. EPM's intellectual property (IP) an

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. ("Kissei"), has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult patients with chronic immune thrombocytopenia (ITP). T

PISCATAWAY, N.J., Sept. 23, 2019 /PRNewswire/ -- GenScript®, the world's leading gene synthesis provider, today announced that it will provide research support to Harvard University scientist George Church, PhD, for his contributions to the Ultra-safe Cell project, the first gr

PHILADELPHIA, Sept. 23, 2019 /PRNewswire/ -- Proton Therapy Partners (PTP) is pleased to announce the addition of three new members to its Board of Directors, Neil Jesuele, Bruce Lawrence and Michael G. Rock, M.D. Each of these individuals possesses vast industry knowledge a